Closing the Gap Between
Technology Promise & Patient Outcomes
Teqfocus and Lumata have built the foundation together — AWS optimization, data automation, and standardized client onboarding are live. The next phase layers AI across coordinator workflows, patient persistence, and prior authorization to unlock $3.2M–$9.5M in measurable annual value for Lumata’s PSP programs.
Tech-enabled Services Powered By Patient Platform
Board Investment Case · Teqfocus × Lumata
Unified Patient
Care Platform
Care Platform
A 12-month platform sprint to transform how ophthalmology specialty practices manage complex biologics — connecting patient engagement, drug utilization, and therapy adherence at scale.
→ View Business Model
→ ROI & Financials
→ See Sprint Plan ↓
12 mo
Full Platform Sprint
+77%
Target Margin at Scale
4 Sprints
Modular Delivery
ICP Target
Ophthalmology specialty practices managing complex biologics (wet AMD, diabetic retinopathy) — under-resourced for patient engagement, drug utilization, and therapy adherence at scale
Platform Investment — 12-Month Sprint Plan · Click any sprint to expand
S1
$120–160K
▾
Capability
Unified patient, clinical & program data model · HIPAA-compliant integration layer · Connected vendor, EMR & enrollment data feeds
Benefit Unlocked
Full patient journey visibility · Operational insight across all programs · Foundation enabling every capability that follows
S2
$35–50K / mo
▾
Capability
Intake & enrollment automation · Intelligent Prior Authorization engine · Next-best-action guidance for care coordinators
Benefit Unlocked
Same-day enrollment (vs. 3–5 day lag) · PA cycle 10 days → 2–3 days · Coordinator hours freed — first measurable ROI
S3
$35–50K / mo
▾
Capability
Adherence & outcomes reporting · Drug utilization analytics · Commercial reporting layer for practices and pharma partners
Benefit Unlocked
Platform becomes an externally valuable service · Retina practices gain data never previously available · First commercial proof point
S4
$35–50K / mo
▾
Capability
HCP & practice guidance portal · Patient engagement and personalised adherence layer · Service packaged as repeatable offering
Benefit Unlocked
Platform is a scalable, marketable product · Revenue begins scaling · Cost curve flattens — margin expansion accelerates
Financial Trajectory
Investment vs Revenue vs Margin % across the 12-month sprint plan and scale phase
Investment
Revenue
Margin %
Patient Outcomes
Improved adherence, earlier AMD intervention, reduced therapy gaps — outcomes measurable in real time
Practice Revenue
Increased specialty drug utilization, faster time-to-therapy, new data-driven revenue streams for practices
Operational Efficiency
Reduced admin burden, managed drug program complexity — clinical staff redirected from paperwork to patients
Business Model
Two Paths to Market
Option B is the recommended model — recurring revenue, defensible moat, outcomes-led positioning with Lumata.
Option A — Technology Reseller
- Platform license sales
- Transactional revenue model
- Lower margin, commoditises over time
- Limited competitive moat
Modeled✓
Option B — Tech-Enabled Service
- Recurring per-patient revenue
- Platform built once — scales with each new practice
- Outcomes & platform bundled as managed service
- Defensible margin expansion over time
- Lumata as category-defining ophthalmology tech partner
Sprint Timeline
Sprint 1 — Data Foundation
Wk 1–10
Sprint 2 — AI + Automation
Mo 3–5
Sprint 3 — Analytics + Outcomes
Mo 5–8
Sprint 4 — Digital Experience
Mo 8–12
Scale Phase
Mo 12+
Investment Structure
Sprint 1 Build
$120–160K
Sprints 2–4 Retainer
$35–50K/mo
Breakeven
Sprint 3 Phase
Margin at Scale
+77%
ICP Profile
Specialty
Ophthalmology
Therapy Area
Wet AMD, Diabetic Retinopathy
Drug Type
Complex Biologics
Pain
Patient engagement at scale
Key KPIs Unlocked
PA Cycle Time
10 days → 2–3 days
Enrollment Speed
Same-day vs 3–5 day
First Measurable ROI
Sprint 2 milestone
Commercial Proof Point
Sprint 3 milestone
Financial Model
Return on Investment
Quantifiable annual value vs. Teqfocus engagement investment across all value drivers.
Total Quantifiable Annual Value
$3.2M – $9.5M
Conservative to realistic range · Excludes strategic RWE value
16×–47×
ROI Ratio
$120–200K
Teqfocus Investment
+77%
Margin at Scale
| Value Driver | Est. Annual Value | Relative Impact | Basis |
|---|---|---|---|
| Invoice Reconciliation Error Reduction | $150K–$400K | Est. 2–5% of annual invoice value paid in error; total invoiced ~$8–12M | |
| Coordinator Time Savings | $120K–$240K | 3–5 hrs/week × 12 NCMs × $65/hr × 52 weeks; SRF extraction saves ~1.5 hrs/patient | |
| Revenue Protected — NBA Persistence Uplift | $2.5M–$8M | 10–14% persistence improvement × ~600 patients × $30K annual drug revenue | |
| Hospitalisation Avoidance (Better Adherence) | $400K–$800K | 28% reduction × 8 hospitalisations/100 patients × ~600 patients × $14K avg cost | |
| Escalation Resolution Time Savings | $60K–$100K | 30% reduction in escalation resolution time × fully-loaded team cost | |
| RWE Asset Value — CADTH / Provincial | Strategic | Each provincial listing = $2–5M revenue protection; not quantified here | |
| Total Quantifiable Annual Value | $3.2M–$9.5M | Conservative–realistic range; excludes strategic RWE |
Value Driver Breakdown
Min vs Max annual value by driver — red dashed line = Teqfocus investment
Min Value
Max Value
Investment
Technology Partners
Built on the platforms Lumata's data estate demands
Teqfocus brings Salesforce Summit, Snowflake Premier, AWS Advanced, and Databricks credentials — the right tool for the right layer, without single-vendor lock-in.
- Summit Consulting Partner
- 200+ Certified Experts
- Sales Cloud, Agentforce, Data Cloud
- Agentforce deployments for Hi-Tech enterprises
- Premier Services Partner
- 20+ SnowPro Certified
- 50+ customers
- Cortex Agents architecture, dbt governance, and data fabric design
- Certified Consulting Partner
- 20+ AI & data workloads
- MLOps pipelines
- AI governance frameworks and model monitoring
- Advanced Consulting Partner
- Data & Analytics Competency
- 150+ active engagements
- Cloud architecture for enterprise data platforms
Executive Working Session
Turn Proven Foundations Into Measurable Patient Outcomes.
Explore the path to $3.2M–$9.5M in measurable annual value.
